A double‐blind, randomized, placebo‐controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users,Bipolar Disorders

当前位置： X-MOL 学术 › Bipolar Disord. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A double‐blind, randomized, placebo‐controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users
Bipolar Disorders ( IF 5.0 ) Pub Date : 2020-07-04 , DOI: 10.1111/bdi.12973
Jocelyn Fotso Soh _{1,

2} , Serge Beaulieu ₂ , Francesco Trepiccione ₃ , Outi Linnaranta ₂ , Gabriela Torres-Platas ₁ , Robert W Platt ₄ , Suzane Renaud ₂ , Chien-Lin Su ₄ , Istvan Mucsi ₅ , Luciano D'Apolito ₆ , Benoit H Mulsant ₇ , Andrea Levinson ₇ , Sybille Saury ₂ , Daniel Müller ₇ , Ayal Schaffer ₈ , Annemiek Dols ₉ , Nancy Low ₁₀ , Pablo Cervantes ₁₀ , Birgitte M Christensen ₁₁ , Nathan Herrmann ₈ , Tarek Rajji ₇ , Soham Rej _{1,

2}

Affiliation

Geri-PARTy Research Group, Jewish General Hospital, Montreal, QC, Canada.
Douglas Mental Health University Institute, Montreal, QC, Canada.
Division of Nephrology, University of Naples, Naples, Italy.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University Health Centre, Montreal, QC, Canada.
Division of Nephrology, University Health Network, University of Toronto (UofT), Toronto, ON, Canada.
Biogem S.c.a.r.l., Istituto di Ricerche Genetiche "Gaetano Salvatore", Ariano Irpino, Italy.
Department of Psychiatry, Centre for Addiction and Mental Health & Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Department of Psychiatry, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Amsterdam UMC, Department of Psychiatry, GGZinGeest, Neuroscience, Amsterdam, The Netherlands.
Department of Psychiatry, McGill University Health Centre, Montreal, QC, Canada.
Department of Biomedicine, University of Aarhus, Aarhus, Denmark.

Lithium remains an important treatment for mood disorders but is associated with kidney disease. Nephrogenic diabetes insipidus (NDI) is associated with up to 3‐fold risk of incident chronic kidney disease among lithium users. There are limited randomized controlled trials (RCT) for treatments of lithium‐induced NDI, and existing therapies can be poorly tolerated. Therefore, novel treatments are needed for lithium‐induced NDI.

中文翻译：

阿托伐他汀用于锂使用者肾病性尿崩症的双盲，随机，安慰剂对照试验

锂仍然是情绪障碍的重要治疗方法，但与肾脏疾病有关。锂使用者中，肾性尿崩症（NDI）与发生慢性肾脏疾病的风险高达3倍相关。对于锂诱导的NDI的治疗，有有限的随机对照试验（RCT），并且现有的疗法耐受性差。因此，锂诱导的NDI需要新的治疗方法。

更新日期：2020-07-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11